Menopause and Heart Failure Overlap Creates Diagnostic Challenges, Demands Heightened Awareness
Background
The co-occurrence of heart failure and menopause in middle-aged women presents significant diagnostic challenges due to shared symptomatology. Physiological changes during menopause, particularly the decline in oestrogen, are implicated in predisposing women to cardiac symptoms and cardiovascular disease. Oestrogen typically exerts cardioprotective effects via anti-inflammatory and vasodilatory pathways, and its reduction is linked to myocardial fibrosis and diastolic dysfunction. This overlap often leads to unrecognised cardiac pathology, hindering timely intervention and appropriate management.
Study Design
This review synthesizes current evidence on the intricate intersection between menopause and heart failure. It elucidates shared pathophysiological mechanisms contributing to their co-existence and proposes practical strategies to enhance diagnostic accuracy. The review also aims to improve therapeutic decision-making for clinicians managing perimenopausal women, focusing on how to differentiate menopausal symptoms from underlying cardiac conditions and ensure appropriate, guideline-directed treatments for both conditions.
Results
Epidemiological studies consistently demonstrate that early menopause independently predicts incident heart failure, with a graded increase in risk observed at younger ages of onset. The decline in oestrogen is a key mechanistic explanation, as it normally provides cardioprotective effects through anti-inflammatory and vasodilatory pathways. Its reduction contributes to adverse cardiac remodeling, including myocardial fibrosis and diastolic dysfunction. Traditional perimenopausal symptoms such as fatigue, shortness of breath, sleep disturbance, and palpitations frequently overlap with those of heart failure. > This overlap means these common symptoms may represent unrecognised cardiac pathology, underscoring the need for careful evaluation. Objective investigations, including natriuretic peptides, echocardiography, electrocardiography, and chest X-ray, remain reliable diagnostic tools in this vulnerable group, allowing for independent treatment of both conditions.
Key Findings
- Early menopause independently predicts incident heart failure, with risk increasing at younger ages of onset.
- Oestrogen decline is a mechanistic driver for myocardial fibrosis and diastolic dysfunction in menopausal women.
- Common perimenopausal symptoms (fatigue, shortness of breath) often mask unrecognised cardiac pathology.
- Objective investigations like
natriuretic peptidesandechocardiographyare reliable for diagnosing heart failure in this group. - Both heart failure and menopause can be treated independently with guideline-directed therapies once identified.
Why It Matters
For clinicians and patients, this review highlights the critical need to consider underlying cardiac pathology when perimenopausal women present with common, non-specific symptoms. Heightened awareness of the symptomatic overlap between menopause and heart failure is essential for timely identification and management. It implies that a comprehensive diagnostic approach, utilizing objective investigations like natriuretic peptides and echocardiography, should be routinely considered. This shift in clinical perspective can prevent misdiagnosis, facilitate earlier intervention for heart failure, and ensure that both menopause and heart failure receive appropriate, guideline-directed therapies, ultimately improving long-term cardiovascular outcomes for women.
menopause
heart-failure
cardiovascular-disease
oestrogen
womens-health
diagnosis